

NCIC CLINICAL TRIALS GROUP

**CO.20 INVESTIGATOR AND CRA MEETING –
TRIAL MANAGEMENT AND EDC****AGENDA****OPEN SESSION**

Venue: Delta Chelsea Hotel, Toronto

Date: Friday, May 2nd, 2008

Time: 4:00 pm – 7:00 pm

Chair: Dr. Chris O'Callaghan

4:00 pm	WELCOME AND INTRODUCTION	Dr L. Siu
4:05 pm	CO.20 TRIAL OVERVIEW	Dr L. Siu
	CO.20: A phase III randomized study of Brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbix [®]) versus placebo in combination with Cetuximab (Erbix [®]) in patients previously treated with combination chemotherapy for metastatic colorectal carcinoma	
4:30 pm	UPDATE ON BRIVANIB ALANINATE	Dr I. Walters
4:55 pm	ELECTRONIC DATA CAPTURE	C. Winch
6:45 pm	SITE ACTIVATION LETTER & TISSUE BANKING	Dr C. O'Callaghan
6:55 pm	CLOSING REMARKS & ADJOURNMENT	Dr C. O'Callaghan